|
The International Verapamil-Trandolapril Study (INVEST)
This prospective, randomized, open, blinded-end point evaluation (PROBE) trial is the largest clinical study to date of patients with both hypertension and coronary artery disease. It was designed to determine if a verapamil-based treatment strategy was equivalent to an atenolol-based treatment strategy for reducing all-cause mortality, nonfatal myocardial infarction, or nonfatal stroke in hypertensive patients with coronary artery disease.
This CME activity has been approved for AMA PRA credit.
|
|
